Founded in 2018 by Bård Anders and Stig Olav Kasin, PortalOne is the world’s first hybrid games platform. Hybrid games are a new category of entertainment that seamlessly mix games with live shows that are embedded directly inside the games. This mobile-first content gives users a more engaging games experience, with stunning visuals and enhanced interactivity while allowing users to compete for prizes. We enrich everyday life by providing captivating, positive entertainment — with rewarding interactions that transform virtual wins into real-world rewards. PortalOne is US-based with a subsidiary in Oslo, Norway Hybrid Games are a whole new category of unique gaming entertainment. We harness the power of the Unreal Engine and other technologies to create unique content with stunning visuals and interactivity.We have global financial backing and global partners.

We are developing a new environmentally friendly technology to replace the existing high energy time-consuming procedure in the greenhouses, to help the farmers grow plants faster with better quality and less consumption of energy. Our treatment can be used to control plant size, quality, and speed of growth, and also to preserve plants for a long period.

Cavai AS was founded in December 2017 with the goal of revolutionizing online advertising. User experiences have largely been neglected on the web, and Cavai saw early on that chatbot technology, which has initially been used in customer service, could be a wonderfully good advertising product. Usually, chatbot technology is used as customer service on its own website, while Cavai's platform is built to be able to use chatbot technology on millions of websites for contextual advertising. The team today consists of 15 people, and the product has been launched in Norway, Finland, Sweden and the UK with 50 paying customers. Customers are very pleased and report that Cavai's technology is having a very good effect on completed advertising campaigns. Cavai will have its first month of positive operating results in October and looks to have sales of around 3 million in 2019. Next year will be a big growth year, where we have budgeted with a turnover of NOK 41 million. This growth has also been discussed by Finansavisen, where as part of Finansavisen's web-TV series "Vext", Cavai filmed his meeting with advertising legend Sir Marting Sorell in London. For more information, see https://finansavisen.no/vext/tech/2019/10/23/7465643/chatbot-company-cavai-2020-blir-the-store-growst>  To finance further growth, we are now running a seed funding round of NOK 9.5 - 15 million. The company is priced at NOK 60 million pre-money. For more information see the investor summary, investor presentation and subscription form attached.

Tubeify.tv is the world’s first video site to aggregate videos in a smart and automated way from social media platforms, to provide a full-service website with popular and trending videos, social feeds and merchandise from our video partners. Tubeify.tv does not store any videos in its platform but uses different technologies and business models to partner, source and ingest the most popular videos. Automatic data collection, smart tagging and user behavior tracking provide for enhanced customer experiences and builds engagement Tubeify’s hallmarks include: 1) A well targeted user experience for the Gen ZY audience , with a smart use of data and editors’ curation to show cool and trending videos. 2) An Eshop for creators, influencers and partners’ channel merchandise 3) A branded channel page for video partners’ social media activities Tubeify is Headquartered in Norway, with a skilled management team located in the Nordics, UK, USA and Canada.

Grasp Your Future Our goal is to increase effectiveness and efficiency of medical treatments through person-centered care and improved clinician-patient communication. Grasp concept One-minute video presenting how Grasp works. Grasp Tracker A patented, CE-marked, and approved medical device. You simply squeeze the device when tracking your symptoms, behavior, and events. Grasp User app Through the user app, the doctor is connected to the patient´s everyday life in real-time: at home, at work, or while engaging in activities. Grasp Clinical solution The doctor can remotely and easily adjust the treatment, modify medical plans or give tailored behavioral feedback to increase the function of the patient

We develop business with positive impact on the environment and society – creating more with less based on game changing new technologies. Our ambition is to create synergies of resources available, from the Earth, from research and between people and networks. Therefore, we have chosen Vili Vé as our name, from the two brothers of Odin who created fjords and mountains out of the resources available from Ymir. Our focus areas are cleantech and life science, our primary market is Europe and Asia, our customers and partners are major manufacturers, distributors, B2B customers and consulting companies. Our team, communication and style reflects diversity and openness, and our teamwork is based on dedication and trust. We want our customers and partners to experience us as competent, genuine and attentive – and proactively focusing on win-win solutions.

Estro has developed a patented solution to improve Fish Health for Norwegian and International Fish farms, the "SeaNest" solution reduce mortality, and facilitate and improve the working environment for both farmer and Fish. A controllable solution for the clean Fish in the Battle against the lice, zero contamination, and no loose parts eliminate the risk of pollution. Easy to Wash and handle. We have signed a full-scale test program with some of the largest companies within the business, and so far with a positive result. First Emission fulfilled mid of 2018, and the commercialization process started.

Bookify is a nationwide search portal targeted to anyone planning meetings, events, conferences, kick-offs, and much more. With different search criteria and filters, you`ll have simple access to meetings and conference venues adapted to your standards. Quick and Easy. Bookify makes it easy to find meeting rooms, function rooms and conference rooms. We also simplify the process for people who have a suitable premise they want to rent out but do not know how to proceed. In the app you can quickly find premises near you, it is easy to find the premises that have the facilities you are looking for and payment is done seamlessly right in the app! The app uses geolocation so that you can quickly book the premises you are looking for. At the same time, you can also do more advanced searches to book ahead of time. You have a full overview of upcoming meeting rooms, payment history and receipt archives. In addition, you can add premises you use often as favorites to make the booking process even easier and faster!

The Founder Institute is the world’s premier startup launch program for talented entrepreneurs. If you are up to the challenge, our comprehensive step-by-step program will give you the structure, mentor support, and network of entrepreneurs you need to start an enduring company. Based in Silicon Valley and with chapters across 60 countries, the Founder Institute's mission is to "Globalize Silicon Valley" and build sustainable startup ecosystems worldwide.

CardiNor AS er et norsk bioteknologiselskap etablert for å håndtere kommersialiseringen av secretoneurin, en ny biomarkør test for hjertekar sykdom. Vår innovasjon er en ny og proprietær hjertekar test – secretoneurin. Secretoneurin er vist å ha sterk prognostisk nytteverdi hos pasienter med hjertesvikt, og den har et særskilt stort potensial hos pasienter med hjerterytmeforstyrrelser (arytmi). Hjertekar sykdom er fortsatt den viktigste dødsårsaken i verden i dag. Ingen av de kjent og etablerte biomarkørene for hjertekar sykdom er til særlig hjelp i valg av medisinske, og eller kirurgiske behandlingsmetoder for å forhindre livstruende hjerterytmeforstyrrelser. Selskapet utvikler nå en brukervennlig forskningstest for å måle secretoneurin blod som vil markedsført og solgt gjennom et nettverk av distributører i Europa og USA. Dette etterfulgt av introduksjonen av et CE-merket produkt for klinisk bruk i Europa og regulatorisk godkjenning i USA. CardiNor-ledelsen har inngående kunnskap om og erfaring fra bioteknologi og diagnostisk industri som dekker hele livssyklus fra oppstart til exit. CardiNor samarbeider med verdensledende akademiske institusjoner og opinionsledere og industri i å utvikle og dokumentere biomarkør testen.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Nanook is a global movement of more than 2400 local travel experts committed to sharing amazing experiences and insider knowledge. Being a partner of Nanook not only require high quality, but we also have non-negotiable rules of local ownership and responsibility towards nature and local communities.

Noroff has campuses in Oslo, Bergen, Stavanger, and Kristiansand. In addition to the Online study capabilities of nearly all study programs. We offer undergraduate degrees in Digital Forensics and Interactive Media with a specialization in either Animation or Games. All our degrees can be completed as a campus student or through online studies. -> We also offer recognition of prior learning, meaning you can be accredited exemption from course subjects based on prior documented education. We offer vocational diploma degrees in Visual Effects (VFX), FrontEnd Development, 3D Design & Animation, Game Design, 3D Films, Sound & Music, Graphic Design, Film Production, Technical Design, Network, and IT. Apply now at www.noroff.no

Pexip enables enterprises and organizations of any size to deploy and use video-based communication and collaboration. The Company’s portfolio of products ranges from self-hosted software to cloud service video solutions. Pexip provides seamless collaboration between previously incompatible video and audio technologies such as professional video conferencing systems, Skype for Business, Microsoft Teams, Google Hangouts Meet, and WebRTC. Pexip’s software-based meeting platform can also be used as a foundation for service provider offerings. Pexip has HQ in Oslo, Norway, main offices in London, UK, New York and Reston, US, and Sydney, Australia, as well as sales offices across the globe. For more information, visit www.pexip.com, or follow @PexipInc on Twitter.